Wells Fargo analyst Nick Abbott maintained a Buy rating on Zymeworks (ZYME – Research Report) on April 28 and set a price target of $45.00. The company's shares closed last Wednesday at $7.03, close to its 52-week low of $4.56. According to TipRanks.com, Abbott has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -43.1% and a 0.0% success rate. Abbott covers the Healthcare sector, focusing on stocks such as TRACON Pharmaceuticals, Arcturus Therapeutics, and Alaunos Therapeutics. Zymeworks has an analyst consensus of Strong Buy, with a price target consensus of $23.20, representing a 224.5% upside.
https://www.tipranks.com/news/blurbs/wells-fargo-thinks-zymeworks-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Zymeworks Charts.
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Zymeworks Charts.